Submitted: 02 Jul 2018
Accepted: 20 Nov 2018
First published online: 17 Dec 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

J Renal Inj Prev. 2019;8(2):116-121.
doi: 10.15171/jrip.2019.22
  Abstract View: 131
  PDF Download: 127

Review

A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome

Anoush Azarfar 1, Mahin Ghorban Sabbagh 2, Yalda Ravanshad 3 * , Mohammad Esmaeeli 1, Hassan MehradMajd 4, Azade Oveisi Sani 1, Sahar Ravanshad 5

1 Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 Department of Community Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran
4 Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5 Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
*Corresponding author: Yalda Ravanshad, Email: Email: yalda.ravanshad@gmail.com

Article

Context: To date, several studies have been done regarding the treatment of atypical hemolytic uremic syndrome (aHUS) which discussed eculizumab as a potential treatment for this syndrome. However, the safety and efficacy of eculizumab were not fully assessed. This study aims to do a systematic review about the efficacy and safety of eculizumab in treatment of aHUS.

Evidence Acquisitions: An electronic literature search was conducted to identify appropriate studies. We included all randomized trials and observational studies about using eculizumab in aHUS. Two independent reviewers extracted data from the articles according to the selection criteria.

Results: Eligible studies were included in this systematic review. The literature search and reference mining yielded 571 potential relevant articles. We removed 173 articles because of duplication. We also excluded 245 articles after reviewing the titles and abstracts, and removed 61 studies because the topics were not relevant to the subject. Finally, five studies were included in the systematic review.

Conclusions: Acknowledging the limitations of the study due to the size and nature of the included studies, our systematic review shows that eculizumab was effective in the treatment of aHUS. However, further large randomized trials are suggested.

Implication for health policy/practice/research/medical education:

Eculizumab may be effective in the treatment of aHUS.

Please cite this paper as:Azarfar A, Ghorban Sabbagh M, Ravanshad Y, Esmaeeli M, Mehrad-Majd H, Oveisi Sani A. A systematic review on the efficacy and safety of eculizumab for atypical hemolytic uremic syndrome. J Renal Inj Prev. 2019;8(2):116-121. DOI: 10.15171/jrip.2019.22.

First name
 
Last name
 
Email address
 
Comments
 
Security code


Article Viewed: 131

Your browser does not support the canvas element.


PDF Downloaded: 127

Your browser does not support the canvas element.